My watch list
my.bionity.com  
Login  

Bayer Schering Pharma and EndoCeutics Enter into a Global Agreement for the Development and Commercialization

10-May-2010

Bayer Schering Pharma AG announced that it has signed a global exclusive cooperation agreement with the Canadian company EndoCeutics, Inc. for the development and commercialization of Vaginorm, an intra-vaginal application of dehydroepiandrosterone (DHEA). A Phase III clinical program for Vaginorm in the treatment of symptoms of vulvovaginal atrophy and female sexual dysfunction in postmenopausal women has been initiated. Many women experience changes in vaginal tissue after menopause. These vaginal tissue changes are called vaginal atrophy and they may cause vaginal discomfort including vaginal dryness, itching and burning, and painful sex. Epidemiological research has shown that one quarter to one-half of postmenopausal women suffer from vaginal atrophy.

“Vaginorm is an important late stage addition to our Gynecological Therapy R&D pipeline. We are pleased to work with EndoCeutics towards bringing a new treatment alternative for vaginal atrophy and female sexual dysfunction to an area of high unmet medical need,” said Phil Smits, M.D., Head of Women’s Healthcare at Bayer Schering Pharma. “Gynecological Therapies are a new growth area adding to our contraception business. Our research, in-licensing and innovation efforts are all geared towards this strategic goal.”

EndoCeutics is responsible for conducting the Phase III studies for Vaginorm. Thereafter, Bayer will be responsible for the registration and commercialization of Vaginorm. Under the terms of agreement, EndoCeutics grants Bayer a worldwide, exclusive license to develop, manufacture and commercialize Vaginorm. Further details of the deal have not been disclosed. The transaction is subject to pre-merger notification under the HSR Act.

Facts, background information, dossiers
More about Bayer
  • News

    Bayer: Sales and earnings increased

    The third quarter of 2017 marked a period of further strategic and operational progress for the Bayer Group. “Last quarter we took some important strategic steps,” said Werner Baumann, Chairman of the Board of Management, when he presented the interim report for the third quarter on Thursda ... more

    Novel PET tracer detects small blood clots

    Blood clots in veins and arteries can lead to heart attack, stroke, and pulmonary embolism, which are major causes of mortality. Researchers show that targeting GPIIb/IIIa receptors, the key receptor involved in platelet clumping, with a fluorine-18 (18F) labeled ligand is a promising appro ... more

    Strong start to the year for Bayer

    The Bayer Group got off to a very successful start to 2017 and generated strong sales and earnings growth in the first quarter. “At Pharmaceuticals, we once again benefited from the very good performance of our key growth products,” CEO Werner Baumann said when he presented the interim repo ... more

  • Companies

    Bayer Austria Gesellschaft m.b.H.

    more

    Bayer S.A.

    more

    Bayer S.A.

    more

  • Associations

    Bayer USA Foundation

    Partnering with community leaders and providing philanthropic support have long been a part of Bayer Corporation's culture. In 1953, Bayer created the first of three foundations that later all merged to become the Bayer Foundation. The Bayer Foundation is an endowed 501(c)(3) entity and is ... more

More about Bayer HealthCare
More about Bayer Schering Pharma
  • News

    Lead Discovery Center and Bayer enter into license agreement covering a novel pharmaceutical lead structure

    The Lead Discovery Center GmbH (LDC), based in Dortmund, Germany, a spin-off from Max-Planck-Innovation GmbH (MI) in Munich, with expertise in small molecule pharmaceutical drug discovery, has successfully licensed its first lead structure to a pharma partner. The agreement grants Bayer Sch ... more

    EU regulators okay Qlaira for the treatment of heavy menstrual bleeding

    Bayer Schering Pharma AG, Germany, has successfully concluded the European registration procedure for the introduction of Qlaira in the new indication treatment of heavy menstrual bleeding in women without organic pathology who desire oral contraception. The Netherlands served as Reference ... more

    Bayer launches Betaferon in China

    Bayer Schering Pharma announced the upcoming launch in China of Betaferon® (interferon beta-1b) for the treatment of relapsing-remitting forms of multiple sclerosis (MS). Betaferon is already approved in over 100 countries worldwide. With Betaferon and Gadovist®1.0, which was also recently ... more

  • Companies

    Bayer Schering Pharma AG

    Bayer Schering Pharma’s goal is a leading market position in each of its specialist fields. With its distinctive expertise, the company engages in research on new drugs which, as innovative therapies, make an essential contribution toward improving people’s quality of life. Our outstanding ... more

    Bayer Schering Pharma Oy

    Bayer is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. Our products and services are designed to benefit people and improve their quality of life. At the same time we want to create value through innovation, growth and high earni ... more

    Bayer Schering Pharma AG

    Bayer Schering Pharma’s goal is a leading market position in each of its specialist fields. With its distinctive expertise, the company engages in research on new drugs which, as innovative therapies, make an essential contribution toward improving people’s quality of life. Our outstanding ... more

More about EndoCeutics
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE